Miles A. Miller

5.2k citations

77 papers · 3.9k indexed · 1 hit paper · h-index 33

Co-authors: Ralph Weissleder Rainer H. Köhler Mikäel J. Pittet Douglas A. Lauffenburger Katherine S. Yang Michael F. Cuccarese Camilla Engblom Christina Pfirschke
Topics: Nanoplatforms for cancer theranostics (11 papers)Peptidase Inhibition and Analysis (10 papers)Immune cells in cancer (10 papers)
Cited by: Biomaterials Immunology Oncology
Journals: Proceedings of the National Academy of Sciences Journal of the American Chemical Society Advanced Materials
Partner nations: United States Germany Singapore

In The Last Decade

Miles A. Miller

77 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

2017 504 citations Sean P. Arlauckas, Christopher Garris et al. Science Translational Medicine profile →

Peers

Countries citing papers authored by Miles A. Miller

Since Specialization

Citations

This map shows the geographic impact of Miles A. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miles A. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miles A. Miller more than expected).

Fields of papers citing papers by Miles A. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miles A. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miles A. Miller. The network helps show where Miles A. Miller may publish in the future.

Co-authorship network of co-authors of Miles A. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Miles A. Miller. A scholar is included among the top collaborators of Miles A. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miles A. Miller. Miles A. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Radiation-Triggered Payload Release Enhances Bispecific Antibody Efficacy 2025 ·Cancer Research ·(unknown),(unknown),(unknown),(unknown),(unknown),Thomas S.C. Ng,Ralph Weissleder,Miles A. Miller	1
2	Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin–Drug Conjugate Response 2023 ·Clinical Cancer Research ·Huiyu Hu,Thomas S.C. Ng,Mikyung Kang,(unknown),Ran Li,(unknown),(unknown),(unknown),Ralph Weissleder,Sareh Parangi,Miles A. Miller	5
3	Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release 2022 ·Bioconjugate Chemistry ·(unknown),(unknown),Huiyu Hu,(unknown),(unknown),Sara I. Pai,Sareh Parangi,Ralph Weissleder,Miles A. Miller	21
4	Dual Immunostimulatory Pathway Agonism through a Synthetic Nanocarrier Triggers Robust Anti‐Tumor Immunity in Murine Glioblastoma 2022 ·Advanced Materials ·(unknown),(unknown),Juhyun Oh,Rainer H. Köhler,Hannah Peterson,Xandra O. Breakefield,E. Antonio Chiocca,Miles A. Miller,Christopher Garris,Ralph Weissleder	33
5	Cell–cell communication networks in tissue: Toward quantitatively linking structure with function 2021 ·Current Opinion in Systems Biology ·(unknown),Douglas A. Lauffenburger,Miles A. Miller	3
6	Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer 2021 ·Nature Nanotechnology ·Ran Li,Thomas S.C. Ng,Stephanie J. Wang,Mark Prytyskach,Christopher B. Rodell,Hannes Mikula,Rainer H. Köhler,Michelle A. Garlin,Douglas A. Lauffenburger,Sareh Parangi,Daniela M. Dinulescu,Nabeel Bardeesy,Ralph Weissleder,Miles A. Miller	94
7	In vivo microscopy reveals macrophage polarization locally promotes coherent microtubule dynamics in migrating cancer cells 2020 ·Nature Communications ·(unknown),Ran Li,Stephanie Wang,Mark Prytyskach,Rainer H. Köhler,Douglas A. Lauffenburger,Timothy J. Mitchison,Ralph Weissleder,Miles A. Miller	19
8	Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy 2020 ·Science Advances ·Stephanie J. Wang,Ran Li,Thomas S.C. Ng,(unknown),Madeleine J. Oudin,Mark Prytyskach,Rainer H. Köhler,Ralph Weissleder,Douglas A. Lauffenburger,Miles A. Miller	24
9	In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapybreakdown → 2017 ·Science Translational Medicine ·Sean P. Arlauckas,Christopher Garris,Rainer H. Köhler,Maya Kitaoka,Michael F. Cuccarese,Katherine S. Yang,Miles A. Miller,Jonathan Carlson,Gordon J. Freeman,Robert M. Anthony,Ralph Weissleder,Mikäel J. Pittet	504
10	Near infrared imaging of Mer tyrosine kinase (MERTK) using MERi-SiR reveals tumor associated macrophage uptake in metastatic disease 2017 ·Chemical Communications ·Miles A. Miller,Eunha Kim,Michael F. Cuccarese,(unknown),Mark Prytyskach,Rainer H. Köhler,Mikäel J. Pittet,Ralph Weissleder	21
11	Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts 2017 ·Science Translational Medicine ·Miles A. Miller,Ravi A. Chandra,Michael F. Cuccarese,Christina Pfirschke,Camilla Engblom,Shawn Stapleton,Utsarga Adhikary,Rainer H. Köhler,James F. Mohan,Mikäel J. Pittet,Ralph Weissleder	184
12	Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates 2017 ·Journal of Cancer ·Toshie Yoneyama,Michael C. Gorry,Miles A. Miller,(unknown),Yan Lin,Marcia L. Moss,Linda G. Griffith,Douglas A. Lauffenburger,Laura P. Stabile,James G. Herman,Nikola L. Vujanović	3
13	MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer 2016 ·Molecular Cancer Therapeutics ·Madeleine J. Oudin,(unknown),Claudia Schäfer,Tatsiana Kosciuk,Miles A. Miller,Sangyoon J. Han,Oliver Jonas,Douglas A. Lauffenburger,Frank B. Gertler	34
14	Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance 2016 ·Cancer Discovery ·Miles A. Miller,Madeleine J. Oudin,Ryan J. Sullivan,Stephanie J. Wang,Aaron S. Meyer,Hyungsoon Im,Dennie T. Frederick,Jenny Tadros,Linda G. Griffith,Hakho Lee,Ralph Weissleder,Keith T. Flaherty,Frank B. Gertler,Douglas A. Lauffenburger	138
15	Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer 2016 ·DSpace@MIT (Massachusetts Institute of Technology) ·Miles A. Miller,Ryan J. Sullivan,Douglas A. Lauffenburger	1
16	Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug 2015 ·Nature Communications ·Miles A. Miller,Yao‐Rong Zheng,Suresh Gadde,Christina Pfirschke,Harshal Zope,Camilla Engblom,Rainer H. Köhler,Yoshiko Iwamoto,Katherine S. Yang,Bjorn Askevold,Nagesh Kolishetti,Mikäel J. Pittet,Stephen J. Lippard,Omid C. Farokhzad,Ralph Weissleder	366
17	Low-volume multiplexed proteolytic activity assay and inhibitor analysis through a pico-injector array 2014 ·DSpace@MIT (Massachusetts Institute of Technology) ·(unknown),Tengyang Jing,Chia‐Hung Chen,Miles A. Miller,Douglas A. Lauffenburger	3
18	ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling 2013 ·Proceedings of the National Academy of Sciences ·Miles A. Miller,Aaron S. Meyer,Michael T. Beste,(unknown),(unknown),(unknown),Chia‐Hung Chen,(unknown),Keith Isaacson,Linda G. Griffith,Douglas A. Lauffenburger	75
19	High-Throughput Mutiplexed Protease Activity Measurement Using a Droplet Based Microfluidic Platform with Picoinjector 2012 ·DSpace@MIT (Massachusetts Institute of Technology) ·Chia‐Hung Chen,Miles A. Miller,Aniruddh Sarkar,Michael T. Beste,Douglas A. Lauffenburger,Linda G. Griffith,Jongyoon Han	1
20	Phase I Cancer Trials: A Crucible of Competing Priorities 2001 ·International Anesthesiology Clinics ·Miles A. Miller	10

About Miles A. Miller

Miles A. Miller is a scholar working on Oncology, Immunology and Immunology and Allergy, having authored 77 papers that have together received 3.9k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (11 papers), Peptidase Inhibition and Analysis (10 papers) and Immune cells in cancer (10 papers). The work is most often cited by research in Biomaterials (796 citations), Immunology (1.0k citations) and Oncology (1.1k citations). Miles A. Miller has collaborated with scholars based in United States, Germany and Singapore. Frequent co-authors include Ralph Weissleder, Rainer H. Köhler, Mikäel J. Pittet, Douglas A. Lauffenburger, Katherine S. Yang, Michael F. Cuccarese, Camilla Engblom, Christina Pfirschke, Bjorn Askevold and Christopher Garris. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Advanced Materials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact